clinical trial · NCT06934044
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche·phase1·recruiting·n = 20
Multiple MyelomaCevostamabTocilizumab
brief summary
This study will evaluate the pharmacokinetics (PK), safety, and efficacy of cevostamab in participants with relapsed or refractory (R/R) multiple myeloma (MM).
started
May 13, 2025
primary completion
Nov 4, 2028
completion
Nov 4, 2028
last updated
Apr 13, 2026
official title
A Phase Ib, Open-Label, Single-Arm, Multicenter Trial Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Patients With Relapsed or Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol